Trials / Completed
CompletedNCT00165698
Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 240 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- Female
- Age
- 45 Years – 75 Years
- Healthy volunteers
- —
Summary
To determine the effect and safety of menatetrenone on treatment of postmenopausal osteoporosis comparing with alfacalcidol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | menatetranone | 15 mg three times a day orally for 12 months |
| DRUG | alfacalcidol | 0.25 μg twice a day orally for 12 months |
Timeline
- Start date
- 2005-05-01
- Primary completion
- 2007-01-01
- Completion
- 2007-07-01
- First posted
- 2005-09-14
- Last updated
- 2014-07-22
- Results posted
- 2011-08-11
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00165698. Inclusion in this directory is not an endorsement.